Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27484676 | 0.84 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL23199272 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL23525267 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL12912355 | 0.79 | ALDH1A1 (0.56) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL2771120 | 0.78 | MAPT (0.50) | MAPTALDH1A1HPGDGAAHTT | |
| SCHEMBL5724018 | 0.77 | SMN1; SMN2 (0.51) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL13713047 | 0.77 | SMN1; SMN2 (0.54) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL5724109 | 0.76 | SMN1; SMN2 (0.51) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL10639271 | 0.76 | SMN1; SMN2 (0.50) | MAPTALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL6401181 | 0.76 | SMN1; SMN2 (0.50) | MAPTALDH1A1SMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084445-B2 | Broad-spectrum carbapenems | VenatoRx Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20210188851-A1 | BROAD-SPECTRUM CARBAPENEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-24 | — | — | US | disclosed |
| EP-3802538-A1 | BROAD-SPECTRUM CARBAPENEMS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112513043-A | Broad spectrum carbapenems | 维纳拓尔斯制药公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188851-A1 | BROAD-SPECTRUM CARBAPENEMS | MGAM, ALPI, SI | MAPT 3803/4885ALDH1A1 3603/4885SMN1; SMN2 2268/4885 |
| US-12084445-B2 | Broad-spectrum carbapenems | MGAM, ALPI, SI | MAPT 3803/4885ALDH1A1 3603/4885SMN1; SMN2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.